RxDoctor Payments Data

Lee Glickman, MD

Cardiovascular Disease · Pennington, NJNPI 1295702884

Payments from drug & device makers

$35,063in general payments, 2019–2025

Across 216 payments — averaging $162.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$31K
  • Medtronic$1K
  • Merck$535
  • Amgen$464
  • Novartis$441
  • Boston Scientific$355
  • plus $1K from 14 others

What the payments were for

  • Consulting fees$3001%
  • Speaking & faculty fees$27,95080%
  • Travel & lodging$2,1236%
  • Food & beverage$4,56713%
  • Education$1220%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$35,063 in reported general payments places this provider in the 90th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$130,672
Medicare patients
584
Services billed
1,925

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban278$335,871
EliquisApixaban147$161,063
MultaqDronedarone Hcl84$122,036
Repatha SureclickEvolocumab63$73,196
EntrestoSacubitril/Valsartan56$59,374
Carvedilol ErCarvedilol Phosphate43$29,185
VascepaIcosapent Ethyl48$23,792
Praluent PenAlirocumab25$20,985
BrilintaTicagrelor22$20,026
FarxigaDapagliflozin Propanediol26$19,387
JardianceEmpagliflozin18$18,702
Icosapent Ethyl36$15,616
Metoprolol Succinate624$9,634
Rosuvastatin Calcium515$7,307
Ezetimibe244$5,523

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$30,668$335,871278 claims
PfizerEliquis$97$161,063147 claims
Sanofi-aventis U.S. LLCMultaq$31$122,03684 claims
NovartisEntresto$441$59,37456 claims
AstraZenecaBrilinta, Farxiga$70$39,41348 claims
Boehringer IngelheimJardiance$38$18,70218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Pennington

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →